Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of oral brepocitinib in adults with dermatomyositis
MOH_2022-12-21_012250Phase 3Recruiting
- Sponsor
- Priovant Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brepocitinib in dermatomyositis (DM) (3 arms), sponsored by Priovant Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
brepocitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on MOH_2022-12-21_012250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-21_012250.